Canaccord Genuity Reiterates Buy on Immunogen, Maintains $19 Price Target
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst John Newman has reiterated a Buy rating on Immunogen (NASDAQ: IMGN) and maintained a $19 price target.
June 12, 2023 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman reiterated a Buy rating on Immunogen (NASDAQ: IMGN) and maintained a $19 price target.
The reiteration of a Buy rating and maintenance of a $19 price target by Canaccord Genuity analyst John Newman indicates a positive outlook for Immunogen's stock. This news is directly related to IMGN and is important for investors as it suggests potential upside in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100